Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Molecules (Basel, Switzerland)|September 9, 2022
Radionuclides for Targeted Therapy: Physical PropertiesCaroline Stokke, Monika Kvassheim, Johan BlakkisrudCancers|February 25, 2023
Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATERagnar Bruvoll, Johan Blakkisrud, Lars Tore Mikalsen, et al.Molecular Imaging and Biology|April 29, 2022
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.Acta Oncologica (Stockholm, Sweden)|August 24, 2021
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variableJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2016
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide ConjugateJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patientsCaroline Stokke, Johan Blakkisrud, Ayca Løndalen, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 16, 2020
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphomaAyca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.EJNMMI Physics|December 4, 2025
Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [177Lu]Lu-PSMA-617 RLT including a novel method with active marrow localizationAvery B Peterson, Scott J Wilderman, Johan Blakkisrud, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2017
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab SatetraxetanJohan Blakkisrud, Jon Erik Holtedahl, Ayca Løndalen, et al.Frontiers in Medicine|February 27, 2023
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasisSimen Rykkje Grønningsæter, Johan Blakkisrud, Silje Selboe, et al.Pageof 2